Duloxetine for chronic osteoarthritis pain; an important alternative?

Completed

• Conditions: osteoarthritis; hip; knee; chronic pain; duloxetine; general practice; artrose; heup; knie; chronische pijn

• Registration Number: NL-OMON26725
• Lead Sponsor: Erasmus MCZonMw

Brief Summary

van den Driest JJ, Schiphof D, Luijsterburg PAJ, et al. Effectiveness and costeffectiveness of duloxetine added to usual care for patients with chronic pain due to hip or knee osteoarthritis: protocol of a pragmatic openlabel cluster randomised trial (the DUO trial). BMJ Open 2017;7:e018661. doi:10.1136/ bmjopen-2017-018661 van den Driest JJ, Schiphof D, Koffeman AR et al. No added value of duloxetine in patients with chronic pain due to hip or knee osteoarthritis: a cluster-randomized trial. Arthritis Rehumatol 2022; Jan 6. doi: 10.1002/art.42040

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 362

Inclusion Criteria

1) having hip or knee OA based on the clinical ACR criteria, and 2) having chronic pain (most days of the last three months) in hip or knee, and 3) either: (i) a contra-indication for NSAIDs; (ii) adverse reactions of NSAIDs; or (iii) insufficient benefit of NSAIDs.

Exclusion Criteria

1) on waiting list for hip/knee replacement, and 2) use of antidepressants, 3) contra-indication of duloxetine (use of Monoamine Oxidase Inhibitors, having uncontrolled narrow-angle glaucoma, in combination with (other) central nervous system acting drugs, in combination with thioridazine, hypersensitivity to duloxetine)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain at 3 months measured with the WOMAC pain subscale

Secondary Outcome Measures

Name	Time	Method
Pain at 1 year (WOMAC pain subscale), Disability (WOMAC function subscale)<br /><br>Adverse reactions <br /><br>Quality of life with the EQ-5D <br /><br>Compliance to treatment (Brief Medication Questionnaire)<br /><br>Patients’ satisfaction <br /><br>OARSI-OMERACT responder criteria <br /><br>Costs; including direct medical and patient costs (iMCQ) and productivity costs (iPCQ).